Critical pathophysiological roles of a potential therapeutic target RHBDL2 in triple negative breast cancer

被引：0
|
作者：
Okumura, Kazumasa [1 ,2 ,3 ]
Matsushita, Yosuke [1 ]
Komatsu, Masato [1 ]
Kimura, Ryuichiro [1 ]
Yoshimaru, Tetsuro [1 ]
Ono, Masaya [4 ]
Miyoshi, Yasuo [5 ]
Honda, Junko [6 ]
Sasa, Mitsunori [7 ]
Tangoku, Akira [8 ]
Katagiri, Toyomasa [1 ]
机构：
[1] Tokushima Univ, Inst Genome Res, Div Genome Med, Tokushima, Japan
[2] Tokushima Univ, Dept Thorac Endocrine Surg, Tokushima, Japan
[3] Higashi Tokushima Med Ctr, Dept Surg, Tokushima, Japan
[4] Natl Canc, Div Chemother Clin Res, Tokyo, Japan
[5] Hyogo Coll Med, Dept Surg, Nishinomiya, Hyogo, Japan
[6] Natl Hosp Org Higashitokushima Med Ctr, Dept Surg, Itano, Tokushima, Japan
[7] Tokushima Breast Care Clin, Dept Surg, Tokushima, Japan
[8] Tokushima Univ, Dept Thorac Endocrine Surg, Tokushima, Japan
来源：
CANCER SCIENCE | 2018年 / 109卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P-2279
引用
收藏
页码：960 / 960
页数：1
相关论文
共 50 条
  • [41] The sigma-2 receptor as a target for therapeutic drug delivery in triple negative breast cancer
    Makvandi, Mehran
    Tilahun, Estifanos D.
    Lieberman, Brian P.
    Xu, Kuiying
    Zeng, Chenbo
    Hou, Catherine
    Mach, Robert H.
    CANCER RESEARCH, 2016, 76
  • [42] Src: a potential target for the treatment of triple-negative breast cancer
    Tryfonopoulos, D.
    Walsh, S.
    Collins, D. M.
    Flanagan, L.
    Quinn, C.
    Corkery, B.
    McDermott, E. W.
    Evoy, D.
    Pierce, A.
    O'Donovan, N.
    Crown, J.
    Duffy, M. J.
    ANNALS OF ONCOLOGY, 2011, 22 (10) : 2234 - 2240
  • [43] Ferroptosis and triple-negative breast cancer: Potential therapeutic targets
    Xu, Na
    Li, Baohong
    Liu, Yong
    Yang, Cui
    Tang, Siqi
    Cho, William C.
    Huang, Zunnan
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [44] Pathogenesis and Potential Therapeutic Targets for Triple-Negative Breast Cancer
    Li, Chia-Jung
    Tzeng, Yen-Dun Tony
    Chiu, Yi-Han
    Lin, Hung-Yu
    Hou, Ming-Feng
    Chu, Pei-Yi
    CANCERS, 2021, 13 (12)
  • [45] Therapeutic potential of Fingolimod in triple negative breast cancer preclinical models
    Rupp, Tristan
    Pelouin, Oceane
    Genest, Laurie
    Legrand, Christophe
    Froget, Guillaume
    Castagne, Vincent
    TRANSLATIONAL ONCOLOGY, 2021, 14 (01):
  • [46] Prenylated Stilbenoids as Potential Therapeutic Agents for Triple Negative Breast Cancer
    Mohammad-Hosseinpour, Sepideh
    Ho, Linh-Chi
    Long, Cecily
    Medina-Bolivar, Fabricio
    IN VITRO CELLULAR & DEVELOPMENTAL BIOLOGY-ANIMAL, 2020, 56 (01) : S21 - S21
  • [47] Implication of IZUMO2 in the cell-in-cell phenomenon: A potential therapeutic target for triple-negative breast cancer
    Higashi, Toshiya
    Saigo, Chiemi
    Chikaishi, Wakana
    Hayashi, Hirokatsu
    Hanamatsu, Yuki
    Futamura, Manabu
    Matsuhashi, Nobuhisa
    Takeuchi, Tamotsu
    THORACIC CANCER, 2024, 15 (07) : 513 - 518
  • [48] ADAM17: A new therapeutic target for triple negative breast cancer?
    McGowan, P.
    Mullooly, M.
    Sukor, S.
    O'Donovan, N.
    Duffy, M. J.
    EJC SUPPLEMENTS, 2010, 8 (07): : 47 - 47
  • [49] CHK1 AS A THERAPEUTIC TARGET IN TRIPLE-NEGATIVE BREAST CANCER
    Quidville, V.
    Albiges-Sauvin, L.
    Goubar, A.
    Scott, V.
    Andre, F.
    ANNALS OF ONCOLOGY, 2011, 22 : 51 - 52
  • [50] Cripto-1 as a novel therapeutic target for triple negative breast cancer
    Castro, Nadia P.
    Fedorova-Abrams, Natalie D.
    Merchant, Anand S.
    Rangel, Maria Cristina
    Nagaoka, Tadahiro
    Karasawa, Hideaki
    Klauzinska, Malgorzata
    Hewitt, Stephen M.
    Biswas, Kajal
    Sharan, Shyam K.
    Salomon, David S.
    ONCOTARGET, 2015, 6 (14) : 11910 - 11929
12345